Drugs / HCP1303
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02715401 | Oct → Nov 2015 | benign prostatic hyperplasia, erectile dysfunction | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02712411 | Jul → Aug 2015 | erectile dysfunction, prostate disorder | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02667938 | Mar 2015 → Jan 2016 | benign prostatic hyperplasia | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-09-27 | Hanmi Pharmaceutical Company Limited | Results <보도자료> ‘탐스로신·타다라필 복합제’ 3상 결과 세계성의학회 임상부문 최우수 연제상 선정 hanmi.co.kr ↗
발표 내용에 따르면, 탐스로신 0.4mg 복합제 투여군에서 대조군 대비 IPSS(국제 전립선 증상 점수)가 약 28% 더 감소되었으며, 성기능 개선 효과는 비열등함을 보였다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-09-27 | Hanmi Pharmaceutical Company Limited | <보도자료> ‘탐스로신·타다라필 복합제’ 3상 결과 세계성의학회 임상부문 최우수 연제상 선정 hanmi.co.kr ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCP1303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02667938 ↗ |